Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Calls Abrupt Halt To Phase III Trials Of Sepsis Drug

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical stopped the Phase III trials of its TAK-242 drug for treating sepsis, but said it was not because of safety or efficacy reasons. The company said it is dropping the drug for strategic reasons, but without elaboration other than the time and investment needed to complete the trials. A spokesman said the firm could decide to license the drug, which already had fast-track review status at the U.S. FDA, to other manufacturers. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel